CellBri Bio-Innovation Wins Global CGT Industry Award

Shenzhen CellBri Bio-Innovation Technology Co., Ltd, a leading developer of automated and integrated manufacturing technologies for cell and gene therapy (CGT), has been honored with the "Global CGT Industry Enabling Technology Innovation Leadership Award" by Frost & Sullivan. The company was recognized for its innovative and efficient solutions that address the industry's persistent challenges of insufficient production capacity and high costs.

Founded in 2020, CellBri is headquartered in Shenzhen and focuses on upstream CGT equipment. Its pioneering "Tools define the process; the process defines the product" philosophy consolidates the entire workflow, cell processing, magnetic bead-based sorting, transduction, expansion, washing, concentration, formulation, and dispensing, into a single standardized platform. This approach enables continuous, automated, and fully traceable manufacturing, significantly reducing the complexity and labor intensity associated with traditional CGT production models.

CellBri's scalable manufacturing capacity and fully integrated closed-loop system have positioned the company as a reliable partner for global biopharma companies. Its 11,000-square-meter state-of-the-art, automated production hub can deliver up to 500,000 consumable sets annually, ensuring high-volume supply chain security. The company's technology has been field-proven across more than 10 countries, supporting over 200 organizations and 100+ advanced therapy pipelines, including landmark commercial MSC approvals and multiple CAR-T therapies.

CellBri's flexible modular architecture and end-to-end closed-loop system provide distinct competitive advantages. By integrating fully enclosed automated unit operations, the company has demonstrated operational efficiency, as evidenced by a collaboration with Fosun Kairos on an autologous dual-target CAR-T program. This partnership reduced cell manufacturing turnaround time to just 48 hours, showcasing the company's capability to deliver rapid and reliable manufacturing solutions.

Frost & Sullivan's award, presented at the 20th Frost & Sullivan Global Growth, Innovation and Leadership (GIL) Summit and the 5th New Investment Event, is based on the company's outstanding performance and remarkable achievements in technological innovation, commercial success, and customer value. The judging panel, consisting of third-party investment and financing experts, financial experts, bankers, and well-known listed company entrepreneurs, rigorously evaluated the nominees and awarded CellBri the "2026 GLOBAL CGT INDUSTRY ENABLING TECHNOLOGY INNOVATION LEADERSHIP AWARD."

The recognition underscores CellBri's commitment to advancing the cell therapy industry through innovative solutions that address industry-wide challenges. With its robust patent portfolio and proven track record, CellBri is poised to continue driving the transformation of cell and gene therapy manufacturing, enabling biopharma developers to lower operational overhead and scale sustainably.